在埃及,心脏衰竭与保存的射出小部分:专家意见
Magdy Abdelhamid1, Amr Zaki Salem2, Hamza Kabil3
1Faculty of Medicine, Cairo University, Cairo, Egypt.
Global heart
|March 24, 2025
概括
在埃及,心力衰竭与保存的喷射分数 (HFpEF) 管理需要标准化诊断和量身定制的多药疗法. -葡萄糖共运输体-2 (SGLT2) 抑制剂是关键,与利尿剂和阿尔多激素对抗剂一起,为最佳的患者结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 公共卫生 公共卫生
背景情况:
- 在全球范围内,心力衰竭与保留喷射分数 (HFpEF) 构成了重大的医疗保健挑战.
- 对HFpEF病理生理学的不充分理解和有限的治疗选择导致疾病控制不良.
- 在埃及,HFpEF的诊断和管理是非标准化的,并由相关疾病和资源限制加剧.
研究的目的:
- 为埃及提供HFpEF流行病学,诊断和治疗的综合审查.
- 讨论当前和新的药理疗法,医疗保健服务和未满足的需求.
- 为临床实践和未来研究途径提出建议.
主要方法:
- 对HFpEF诊断和管理的当前文献的综述.
- 在埃及背景下分析指南规定的评分系统,特别是H2FPEF的实用性.
- 评估多种药物治疗方案,包括SGLT2抑制剂,利尿剂和阿尔多激素对抗剂.
主要成果:
- 在埃及,H2FPEF评分系统通常用于HFpEF诊断.
- 建议根据患者的病情,症状和并发症量身定制的多药疗法.
- -葡萄糖共运输体-2 (SGLT2) 抑制剂被确定为高高压pEF治疗的基石.
结论:
- 标准化诊断方法和基于指导方针的评分系统对于HFpEF管理至关重要.
- 个性化的多种药物治疗策略,包括SGLT2抑制剂,对于改善HFpEF结果至关重要.
- 解决未满足的需求和推进研究对于改善埃及的HFpEF护理服务至关重要.
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: Diuretics
309
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
309
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
01:26Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K